CT-P13: a review on a biosimilar to infliximab in the treatment of inflammatory bowel disease

References

• Old LJ. Tumor necrosis factor [TNF]. Science. 1985;230:630–632.
   PubMed Web of Science ®Google Scholar
• Black RA, Rauch CT, Kozlosky CJ, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-a from cells. Nature. 1997;385:729–733.
   PubMed Web of Science ®Google Scholar
• O’Shea JJ, Ma A, Lipsky P. Cytokines and autoimmunity. Nat Rev Immunol. 2002;2:37–45.
   PubMed Web of Science ®Google Scholar
• Høivik ML, Lydia CT, Buer MC, et al. Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population. Scand J Gastroenterol. 2018;53:6,692–699.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Procedural advice for users of the centralised procedure for similar biological medicinal products applications. EMA/940451/2011. www.ema.europa.eu/docs/enGB/documentlibrary/Regulatory and procedural guideline/2012/04/WC500125166.pdf
   Google Scholar
• World Health Organization, Expert committee on biological standardization. Guidelines on evaluation of similar biotherapeutic products. 2009. www.who.int/biologicals/areas/biologicaltherapeutics/BIOTHERAPEUTICSFORWEB22APRIL2010.pdf
   Google Scholar
• US Food and Drugs Administration. Demonstration of comparability of human biological products, including therapeutic biotechnology-derived products (1996). www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm122879.htm
   Google Scholar
• International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Comparability of biotechnological/biological products subject to changes in their manufacturing process. Q5E;2004. www.ich.org/fileadmin/PublicWebSite/ICHProducts/Guidelines/Quality/Q5E/Step4/Q5EGuideline.pdf
   Google Scholar
• European Medicines Agency. Guideline on similar biological medicinal products. CHMP/437/04 Rev 1. cited 2014 Oct 23 Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. cited 2016 Feb 28.
   Google Scholar
• U. S. Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product: guidance for industry. 2015 Apr. cited 2016 Feb 28. Available from: http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf.
   Google Scholar
• Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013;72(10):1613–1620.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Arthritis Rheum Dis. 2017;76(2):355–363.
   PubMed Web of Science ®Google Scholar
• Yoo DH, Racewicz A, Brzezicki J, et al. A Phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:82.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Miranda P, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76(2):346–354.
   PubMed Web of Science ®Google Scholar
• Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72(10):1605–1612.
   PubMed Web of Science ®Google Scholar
• Park W, Yoo DH, Jaworski J, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.
   PubMed Web of Science ®Google Scholar
• de Ridder L, Benninga MA, Taminiau JA, et al. Infliximab use in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;45(1):3–14.
   PubMed Web of Science ®Google Scholar
• Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs. 2014;6(5):1163–1177.
   PubMed Web of Science ®Google Scholar
• Harris RJ. Processing of C-terminal lysine and arginine residues of proteins isolated from mammalian cell culture. J Chromatogr A. 1995;705(1):129–134.
   PubMed Web of Science ®Google Scholar
• Gabbani T, Deiana S, Annese V. CT-P13: design, development, and place in therapy. Drug Des Devel Ther. 2017 Published 2017 Jun 6;11:1653–1661. .
   PubMed Web of Science ®Google Scholar
• Ki Jung L, Lee SJ, Kim S, et al. Comparable Immune Function Inhibition by the Infliximab biosimilar CT-P13: implications for treatment of inflammatory bowel disease. J Crohn’s Colitis. 2017 May 1;11(5):593–602. .
   Google Scholar
• Montes A, Perez-Pampin E, Joven B, et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015;16(4):333–345.
   PubMed Web of Science ®Google Scholar
• Park W, Lee SJ, Yun J, et al. Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study. Expert Rev Clin Immunol. 2015;11:25–31.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Yamanaka H, Tanaka Y, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25(6):817–824.
   PubMed Web of Science ®Google Scholar
• Kim YH, Ye BD, Pesegova M, et al. Phase III randomized controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn’s disease: 1-year maintenance and switching results. United European Gastroenterol J. 2017;5.supplement 1.
   Google Scholar
• Ye BD, Pesegova M, Alexeeva O, et al. Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn’s disease: an international, randomised, double-blind, phase 3 non-inferiority study. Lancet. 2019 Mar 28;393:1699–1707.
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al., NOR-SWITCH study group. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316. .
   PubMed Web of Science ®Google Scholar
• Goll GL, Jørgensen KK, Sexton J, et al. Long‐term efficacy and safety of biosimilar infliximab (CT‐P13) after switching from originator infliximab: Open‐label extension of the NOR‐SWITCH trial. J Intern Med. 2019. Accepted Author Manuscript. DOI:10.1111/joim.12880
   PubMed Web of Science ®Google Scholar
• Jørgensen KK, Olsen IC, Goll GL, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: explorative subgroup-analyses in Crohn’s disease and ulcerative colitis in the Nor-switch extension trial. United European Gastroenterol J. 2017;5:8.
   Google Scholar
• Chaparro M, Garre A, Guerra Veloz MF, et al. Effectiveness and safety of the switch from Remicade to CT-P13 in patients with inflammatory bowel disease. J Crohn’s Colitis. 2019;jjz070. DOI:10.1093/ecco-jcc/jjz070.
   Google Scholar
• Fiorino G, Manetti N, Armuzzi A, et al. The PROSIT-BIO cohort: a prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm Bowel Dis. 2017;23:233–243.
   PubMed Web of Science ®Google Scholar
• Farkas K, Rutka M, Golovics PA, et al. Efficacy of Infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis. 2016;10(11):1273–1278.
   PubMed Web of Science ®Google Scholar
• Jung YS, Park DI, Kim YH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30(12):1705–1712.
   PubMed Web of Science ®Google Scholar
• Ala K, Avery P, Wilson R, et al. Early experience with biosimilar infliximab at a district general hospital for an entire Crohn’s disease patient cohort switch from Remicade to inflectra. Gut. 2016;65:A81.
   Web of Science ®Google Scholar
• Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol. 2017;29:1290–1295.
   PubMed Web of Science ®Google Scholar
• Bennett KJ, Heap GA, Hawkins S, et al. Prospective evaluation of the safety and efficacy of switching stable patients with inflammatory bowel disease from Remicade™ to biosimilar infliximab (IFX). Gut. 2016;65:A146.
   Web of Science ®Google Scholar
• Boone N, Lui L, Romberg M, et al. Transition study of biosimilar infliximab in patients with inflammatory bowel dise. Clin Ther. 2017;39:e9.
   Google Scholar
• Buer LC, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11:297–304.
   PubMed Web of Science ®Google Scholar
• Choe YH, Lee SH, Park DI, et al. Effectiveness and safety in Crohn’s disease patients who were treated with CT-P13. Gastroenterology. 2017;152:S406.
   Web of Science ®Google Scholar
• Chung L, Arnold B, Johnson R, et al. Making the change: switching to infliximab biosimilars for IBD at North Bristol NHS trust. Gut. 2016;65:A22–A23.
   Web of Science ®Google Scholar
• Díaz Hernández L, Rodríguez González GE, Vela González M, et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months [abstract P449]. J Crohn’s Colitis. 2016;10:S327.
   Google Scholar
• Eberl A, Huoponen S, Pahikkala T, et al. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients. Scand J Gastroenterol. 2017;52:1348–1353.
   PubMed Web of Science ®Google Scholar
• Geccherle A, Tessari R, Variola A, et al. A single-center experience with biosimilar infliximab: clinical, pharmacological and economic aspects. Tech Coloproctol. 2017;21:834.
   Google Scholar
• Farkas K, Rutka M, Balint A, et al. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis – experiences from a single center. Expert Opin Biol Ther. 2015;15(9):1257–1262.
   PubMed Web of Science ®Google Scholar
• Gompertz M, Alfaro L, Ricart E, et al. Infliximab biosimilar CT-P13 in inflammatory bowel disease patients that require intensification treatment. J Crohn’s Colitis. 2017;11:S427–8.
   Google Scholar
• Guerrero Puente L, Iglesias Flores E, Benitez JM, et al. Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission. Gastroenterol Hepatol. 2017;40:595–604.
   PubMed Web of Science ®Google Scholar
• Hamanaka S, Nakagawa T, Koseki H, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single cohort observational study. J Crohn’s Colitis. 2016;10:S260.
   Google Scholar
• Hlavaty T, Krajcovicova A, Sturdik I, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases—a one-year, single-centre retrospective study. Gastroenterol Hepatol. 2016;70:27–36.
   Google Scholar
• Huoponen S, Eberl A, Räsänen P, et al. Switching maintenance-infliximab to biosimilar-infliximab does not lead to significant changes in health-related quality of life and clinical outcomes in inflammatory bowel disease patients. Value Health. 2017;20:A545.
   Web of Science ®Google Scholar
• Kang B, Lee Y, Lee K, et al. Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study. Inflamm Bowel Dis. 2018;24:607–616.
   PubMed Web of Science ®Google Scholar
• Jahnsen J, Jørgensen K. Experience with biosimilar infliximab (RemsimaR) in Norway. Dig Dis. 2017;35(1–2):83–90.
   PubMed Web of Science ®Google Scholar
• Kang Y, Moon H, Lee S, et al. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60(4):951–956.
   PubMed Web of Science ®Google Scholar
• Kolar M, Duricova D, Bortlik M, et al. Infliximab biosimilar (Remsima) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre. Dig Dis. 2017;35:91–100.
   PubMed Web of Science ®Google Scholar
• Nugent S, Nugent M, Mullane D, et al. EirSwitch echoes of NorSwitch: switching biosimilar therapy in an IBD cohort an Irish experience. J Crohn’s Colitis. 2017;11:S295.
   Google Scholar
• Plevris N, Deekae A, Jones GR, et al. A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: The Edinburgh experience. Gastroenterology. 2017;152:S385.
   Web of Science ®Google Scholar
• Rahmany S, Cotton S, Garnish S, et al. In patients with IBD switching from originator infliximab (remicade) to biosimilar infliximab (CT-P13) is safe and effective. Gut. 2016;65:A89.
   Web of Science ®Google Scholar
• Ratnakumaran R, To N, Gracie D, et al. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience. United Eur Gastroenterol J. 2017;5:A524.
   Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690–696.
   PubMed Web of Science ®Google Scholar
• Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47:356–363.
   PubMed Web of Science ®Google Scholar
• Sieczkowska J, Jarzȩbicka D, Oracz G, et al. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2016;62:354.
   Google Scholar
• Sieczkowska J, Jarzebicka D, Banaszkiewicz A, et al. Switching between infliximab originator and biosimilar in pediatric patients with inflammatory bowel disease: preliminary observations. J Crohns Colitis. 2016;10:127–132.
   PubMed Web of Science ®Google Scholar
• Sladek M, Vultaggio A, Ghione S, et al. Efficacy, safety and immunogenicity of CT-P13 following transition from reference infliximab (Remicade) in children with established inflammatory bowel disease: a multi-centre prospective, observational study. J Pediatr Gastroenterol Nutr. 2017;64:52.
   Google Scholar
• Smits LJT, Grelack A, Derikx L, et al. Long-term clinical outcomes after switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2017;62:3117–3122.
   PubMed Web of Science ®Google Scholar
• Strik AS, Van De Vrie W, Megen Y, et al. Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent Crohn’s disease: a prospective study. Gastroenterology. 2017;152:S66.
   Web of Science ®Google Scholar
• Toscano Guzmán MD, Sierra Torres MI, Flores Moreno S, et al. Effectiveness and safety of biosimilar infliximab in ulcerative colitis. Eur J Hosp Pharm. 2016;23:A152.
   Google Scholar
• Bergqvist V, Kadivar M, Molin D, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018 Oct 11;11: 1756284818801244.
   Web of Science ®Google Scholar
• Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut. 2016;65:1132–1138.
   PubMed Web of Science ®Google Scholar
• Fiorino G, Begoña Ruiz-Argüello M, Maguregui A, et al. Full Interchangeability in regard to immunogenicity between the infliximab reference biologic and biosimilars CT-P13 and SB2 in inflammatory bowel disease. Inflamm Bowel Dis. 2018 March;24(3):601–606. .
   PubMed Web of Science ®Google Scholar
• Kolar. Pregnancy outcomes in women with IBD treated with biosimilar infliximab. J Crohn’s Colitis. 2018;12:P614.
   Google Scholar
• Schreiber S, Jang B, Barzan V, et al. Tu2018 - novel formulation of CT-P13 (Infliximab Biosimilar) for subcutaneous administration: initial results from a Phase I open-label randomized controlled trial in patients with active Crohn’s disease. Gastroenterology. 2018;154(6):S–1371
   Web of Science ®Google Scholar
• Westhovens R, Yoo D, Jaworski J, et al. THU0191 Novel formulation of ct-p13 for subcutaneous administration in patients with rheumatoid arthritis: initial results from a phase i/iii randomised controlled trial. Ann Rheumatic Dis. 2018;77:315.
   PubMed Web of Science ®Google Scholar
• Rémuzat C, Kapuśniak A, Caban A, et al. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy. 2017;5(1):1307315.
   PubMedGoogle Scholar
• GaBI Online - Generics and Biosimilars Initiative. Huge discount on biosimilar infliximab in Norway. Mol, Belgium: Pro Pharma Communications International. www.gabionline.net.
   Google Scholar
• Gecse K, Lovasz B, Farkas K, et al. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: aprospective, multicentre, nationwide cohort. J. Crohn’s Colitis. 2016;10(2):133–140.
   Google Scholar
• Keil R, Wasserbauer M, Z´adorov´a Z, et al. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand J Gastroenterol. 2016;51(9):1062–1068.
   PubMed Web of Science ®Google Scholar
• Park S, Kim Y, Lee J, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9(Suppl.1):35–44.
   PubMedGoogle Scholar
• Gonczi L, Kb G, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017 Nov;23(11):1908–1915.
   PubMed Web of Science ®Google Scholar
• Kaniewska M, Moniuszko A, Rydzewska G. The efficacy and safety of the biosimilar product (Inflectra®) compared to the reference drug (Remicade®) in rescue therapy in adult patients with ulcerative colitis. Gastroenterol Rev Gastroenterol Rev. 2017;12:169–174.
   Google Scholar
• Richmond L, Curtis L, Garrick V, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103:89–91.
   PubMed Web of Science ®Google Scholar